BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05295875 (ALT-801 in Obesity): BVCT ex-ante prediction vs. reported outcome

On 20 Nov 2023, BioinvestGPT's BVCT predicted technical success and commercial failure for this trial. The 23 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially insufficient inferior to tirzepatide.

Clinical Trial

NCTID
NCT05295875
Acronym
MOMENTUM
Drug Name
ALT-801
Drug MoA
dual GLP1/glucagon receptor agonist
Drug Modality
peptide biologic
Drug Class
Best-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
Obesity
Human Patients
391
Sponsor
Altimmune
Phase
Phase 2

Prediction of , index 901

Prospective Prediction
Prediction Index
901
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
216 days in advance
Readout Data Interpretation
-13.2% placebo-adjusted weight loss at week 48 (vs -20% placebo-adjusted weight loss at week 48 for tirzepatide 15mg).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially insufficient inferior to tirzepatide
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)
Phase
Phase 2
Status
Completed
Enrollment
391
Lead sponsor
Altimmune, Inc.
Conditions
Obesity/Overweight
Interventions
DRUG: ALT-801; OTHER: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-03-31
Primary completion
2023-09-28
Completion
2023-09-28
Primary outcomes
  • Relative change from baseline in body weight percentage (Baseline to Week 48)

NCT05295875 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials